Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2011 Nov 4;11(1):154–164. doi: 10.1158/1535-7163.MCT-11-0606

Figure 4. Prolonged co-treatment with gefitinib and MK-2206 promotes the switch from autophagy to apoptosis.

Figure 4

(A) LN229 and T98G cells were treated with 5 μM of gefitinib for different time periods, and the levels of LC3 and Bim were examined by Western blot. Tubulin was used as a loading control. (B) LN229 and T98G cells were treated with 5 μM gefitinib for different time periods in the absence or presence of 0.5 μM of MK-2206, and the levels of LC3 and Bim were examined by Western blot. Tubulin was used as a loading control. (C) LN229 and T98G cells were treated with 5 μM of gefitinib for different periods of time in the absence or presence of 0.5 μM of MK-2206. Apoptosis was examined by measuring Annexin V staining using flow cytometry. (D) LN229 and T98G cells were transfected with a Bim siRNA or a non-targeting siRNA, and then treated with gefitinib for 60h in the absence or presence of 0.5 μM of MK-2206. Apoptosis was examined by measuring Annexin V staining using flow cytometry.